This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Scientists have identified a key protein in the development of Alzheimer’s disease which could prove critical in slowing or even halting the condition’s progress.
The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of the drug. Lilly said the US regulator “wants to further understand topics related to evaluating the safety and efficacy of donanemab,” which includes the safety and efficacy results of its pivotal TRAILBLAZER-ALZ 2 study.
In a remarkable display of scientific prowess and commitment to public health, the Indian Council of Medical Research (ICMR) has spearheaded a series of ground-breaking initiatives aimed at tackling infectious diseases and bolstering diagnostic capabilities nationwide, according to its Annual Report 2023.
This review provides guidance on the treatment of obesity in adults, including lifestyle interventions, antiobesity medications, and surgical approaches.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Last August the Food and Drug Administration (“FDA”)/Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule cannabis from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By doing so, FDA/HHS believe that cannabis no longer meets schedule I criteria but does not meet schedule II criteria either.
This chart shows the drugs with the most patents in Netherlands. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Netherlands? appeared first on DrugPatentWatch - Make Better Decisions.
This randomized clinical trial evaluates a computerized clinical decision support system for the management of uncontrolled hypertension in patients with chronic kidney disease.
This randomized clinical trial evaluates a computerized clinical decision support system for the management of uncontrolled hypertension in patients with chronic kidney disease.
SINUVA (mometasone furoate) Intersect ent inc Patent: 7,951,131 Expiration: Mar 12, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of March 10, 2024 appeared first on DrugPatentWatch - Make Better Decisions.
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Study Location Research Center: The University of Texas Southwestern Medical Center Location: 1440 Empire Central Drive, Ste LD4.100, Dallas, TX 75247 Lead Researchers: Sherwood Brown, MD, PhD, MBA and Marlene Freeman, MD IRB: This study has been reviewed and approved by the UT Southwestern Medical Center Institutional Review Board About the Study A number of women grapple with
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content